DaVita Inc

DVA remains in a Stage 2 advancing regime with a long-term uptrend intact. Active Bearish Exhaustion at recent highs suggests a potential reversal bounce, but current price is extended above the rising EMAs and in extreme overbought territory. The medium-term bias remains bullish, but short-term timing is neutral. Aligned with a Free Cash Flow + Buybacks approach, we will stalk for shallow pullbacks into the 9/21 EMA support zone rather than chase extended strength.

• ↑Q4 2025 adj. operating income $586M and EPS $3.40
• ↑2026 EPS guidance raised to $14.10–$15.20 range
• ↓Q4 2025 treatment volumes fell 1.1% YoY